WASHINGTON (Reuters) - A U.S. Food and Drug Administration panel on Thursday recommended Roche Holding AG's eye drug Lucentis for treatment of diabetic macular edema, a leading cause of vision loss among working age people.
via Reuters: Health News Read More Here..
No comments:
Post a Comment